BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nepali K, Chang TY, Lai MJ, Hsu KC, Yen Y, Lin TE, Lee SB, Liou JP. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. Eur J Med Chem 2020;196:112291. [PMID: 32325365 DOI: 10.1016/j.ejmech.2020.112291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci 2021;28:27. [PMID: 33840388 DOI: 10.1186/s12929-021-00721-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hamoud MMS, Pulya S, Osman NA, Bobde Y, Hassan AEA, Abdel-fattah HA, Ghosh B, Ghanim AM. Design, synthesis, and biological evaluation of novel nicotinamide derivatives as potential histone deacetylase-3 inhibitors. New J Chem 2020;44:9671-83. [DOI: 10.1039/d0nj01274b] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
3 Sharma P, LaRosa C, Antwi J, Govindarajan R, Werbovetz KA. Imidazoles as Potential Anticancer Agents: An Update on Recent Studies. Molecules 2021;26:4213. [PMID: 34299488 DOI: 10.3390/molecules26144213] [Reference Citation Analysis]
4 Singh A, Chang TY, Kaur N, Hsu KC, Yen Y, Lin TE, Lai MJ, Lee SB, Liou JP. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. Eur J Med Chem 2021;215:113169. [PMID: 33588178 DOI: 10.1016/j.ejmech.2021.113169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, Xie T, Ye XY. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). Eur J Med Chem 2022;227:113946. [PMID: 34775332 DOI: 10.1016/j.ejmech.2021.113946] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
6 Gandhi A, Masand V, Zaki MEA, Al-Hussain SA, Ghorbal AB, Chapolikar A. Quantitative Structure-Activity Relationship Evaluation of MDA-MB-231 Cell Anti-Proliferative Leads. Molecules 2021;26:4795. [PMID: 34443383 DOI: 10.3390/molecules26164795] [Reference Citation Analysis]
7 Lee HY, Tang DW, Liu CY, Cho EC. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation. Chem Biol Interact 2021;352:109778. [PMID: 34929181 DOI: 10.1016/j.cbi.2021.109778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xing H, Wang P, Liu S, Jing S, Lin J, Yang J, Zhu Y, Yu M. A global integrated analysis of UNC5C down-regulation in cancers: insights from mechanism and combined treatment strategy. Biomedicine & Pharmacotherapy 2021;138:111355. [DOI: 10.1016/j.biopha.2021.111355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chang TY, Nepali K, Chen YY, Yang YSH, Hsu KC, Yen Y, Pan SL, Liou JP, Lee SB. A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling. Biomed Pharmacother 2021;138:111485. [PMID: 33740521 DOI: 10.1016/j.biopha.2021.111485] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pulya S, Patel T, Paul M, Adhikari N, Banerjee S, Routholla G, Biswas S, Jha T, Ghosh B. Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer. European Journal of Medicinal Chemistry 2022;238:114470. [DOI: 10.1016/j.ejmech.2022.114470] [Reference Citation Analysis]
11 Mao P, He W, Mai X, Feng L, Li N, Liao Y, Zhu C, Li J, Chen T, Liu S, Zhang Q, He L. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic & Medicinal Chemistry 2021. [DOI: 10.1016/j.bmc.2021.116599] [Reference Citation Analysis]
12 Maccallini C, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Amoroso R. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals 2022;15:667. [DOI: 10.3390/ph15060667] [Reference Citation Analysis]
13 Sharma R, Chatterjee E, Mathew J, Sharma S, Rao NV, Pan CH, Lee SB, Dhingra A, Grewal AS, Liou JP, Guru SK, Nepali K. Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. Eur J Med Chem 2022;240:114602. [PMID: 35858522 DOI: 10.1016/j.ejmech.2022.114602] [Reference Citation Analysis]
14 Peng X, Li L, Chen J, Ren Y, Liu J, Yu Z, Cao H, Chen J. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. J Med Chem 2022. [PMID: 35043615 DOI: 10.1021/acs.jmedchem.1c01863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Routholla G, Pulya S, Patel T, Adhikari N, Abdul Amin S, Paul M, Bhagavatula S, Biswas S, Jha T, Ghosh B. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model. Bioorg Chem 2021;117:105446. [PMID: 34717237 DOI: 10.1016/j.bioorg.2021.105446] [Reference Citation Analysis]
16 Lee SB, Chang TY, Lee NZ, Yu ZY, Liu CY, Lee HY. Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases. Eur J Med Chem 2022;227:113904. [PMID: 34662748 DOI: 10.1016/j.ejmech.2021.113904] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Frühauf A, Meyer-Almes FJ. Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases. Molecules 2021;26:5151. [PMID: 34500583 DOI: 10.3390/molecules26175151] [Reference Citation Analysis]